字号·· | 护眼
福克斯新闻网

梅奥诊所:阿尔茨海默病血液标志物可预测认知衰退风险Alzheimer’s blood marker could predict cognitive decline risks, says Mayo Clinic

点「原文对照」整页切到原文,或双击某段只看那段的原文。

一项检测与阿尔茨海默病相关蛋白质的血液检测,可能有助于预测老年人是否会在5至10年内出现认知衰退。(iStock)A blood test that detects a protein linked to Alzheimer’s disease could help predict whether older adults will develop cognitive decline within five to 10 years. (iStock)

一项发表在《JAMA Neurology》上的梅奥诊所新研究显示,一种检测与阿尔茨海默病相关蛋白的血液检测,可能有助于预测老年人在五到十年内是否会出现认知能力下降。

A blood test that detects a protein linked to Alzheimer’s disease could help predict whether older adults will develop cognitive decline within five to 10 years, according to a new Mayo Clinic study published in JAMA Neurology.

该研究考察了2178名认知功能正常的成年人血液中磷酸化tau 217(p-tau217)的水平,参与者年龄在60至90岁之间。研究同时还考虑了年龄、性别以及参与者是否携带与阿尔茨海默病风险相关的APOE ε4基因变异。

The study looked at levels of phosphorylated tau 217 (p-tau217) in 2,178 cognitively unimpaired adults, ranging in age from 60 to 90. It also considered age, gender and whether participants carried the APOE ε4 genetic variant, which is associated with Alzheimer’s risk.

这些参与者来自梅奥诊所老龄化研究和阿尔茨海默病神经影像学计划,他们接受了血液生物标志物检测、基因检测以及多次认知评估。

The participants – drawn from the Mayo Clinic Study of Aging and the Alzheimer's Disease Neuroimaging Initiative – underwent blood biomarker testing, genetic testing and multiple cognitive assessments.

研究人员表示,在考虑了p-tau217因素后,APOE ε4与风险呈适度关联,而年龄较大则与更高的风险相关。

While APOE ε4 had a modest association with risk after accounting for p-tau217, older age was associated with greater risk, according to the researchers.

例如,在相同的p-tau217升高水平下,一名65岁老人患轻度认知障碍的五年预估风险为6%,而一名85岁老人的风险则为37%。

For example, at the same elevated p-tau217 level, a 65-year-old faced a 6% estimated five-year risk of mild cognitive impairment, compared to a 37% risk for an 85-year-old.

梅奥诊所神经放射学家、该研究资深作者克利福德·杰克(Clifford Jack Jr.)医学博士指出,阿尔茨海默病的特征是大脑中斑块和缠结的堆积。

Alzheimer’s disease is marked by plaques and tangles that accumulate in the brain, noted senior author Clifford Jack Jr., M.D., a Mayo Clinic neuroradiologist.

他对Fox News Digital表示:“这项检测仅通过抽取血液样本,就能告诉你某人大脑中是否存在这种病理变化。”他补充说,这种病理变化水平越高,与从正常认知进展为认知障碍的风险越大相关。

"The test tells you, just by taking a blood sample, whether someone has that pathology in the brain," he told Fox News Digital, adding that higher levels of the pathology are associated with a greater risk of progressing from normal cognition to impairment.

10种健康状况可能在阿尔茨海默病确诊前数年就与其相关 检测血液中的p-tau217可能比使用PET扫描测量淀粉样蛋白负荷“侵入性更小,且潜在可扩展性更强”,而淀粉样蛋白负荷是阿尔茨海默病的一个标志,与未来的认知障碍相关。

10 HEALTH CONDITIONS MAY BE LINKED TO ALZHEIMER'S YEARS BEFORE DIAGNOSIS Detecting p-tau217 in blood may be "less invasive and potentially more scalable" than using PET scans to measure amyloid burden, a hallmark of Alzheimer’s disease that is associated with future cognitive impairment.

“目标是提供一个个性化的认知障碍发病风险估算,这比单纯报告血液检测对淀粉样蛋白病理呈阳性还是阴性更有意义,”第一作者、梅奥诊所实验室医学与病理学研究员阿利西亚·阿尔格西拉斯-施姆尼希博士在一份新闻稿中说。

"The goal is to provide a personalized estimate of the risk of developing cognitive impairment that is more meaningful than simply reporting whether a blood test is positive or negative for amyloid pathology," said first author Alicia Algeciras-Schimnich, Ph.D., a Mayo Clinic laboratory medicine and pathology researcher, in a news release.

研究人员表示,如果实验性疗法被证实能有效预防或延缓认知衰退,这种血液检测可能会变得更加重要。

If investigational treatments are found to be effective at preventing or delaying cognitive decline, this blood test could take on greater significance, according to the researchers.

阿尔茨海默病的特征是大脑中积聚斑块和缠结。(iStock)Alzheimer’s disease is marked by plaques and tangles that accumulate in the brain. (iStock)

“如果预防性疗法问世,这类信息可以帮助患者和临床医生就治疗的潜在获益与风险进行更知情的对话,”杰克指出。

CLICK HERE TO "If preventive treatments become available, this kind of information could help patients and clinicians have more informed conversations about the potential benefits and risks of treatment," Jack noted.

这些风险估算是在梅奥诊所衰老研究中开发的,该研究取材于一个特定地理区域。“明尼苏达州东南部的老年人群并不代表整个美国,”杰克说。

The risk estimates were developed in the Mayo Clinic Study of Aging, which is drawn from a specific geographical area. "The older population in southeast Minnesota is not representative of the entire United States," Jack said.

虽然该研究的方法可应用于其他人群,但这位研究人员表示,研究结果需要在该区域之外得到复现。

While the study’s methods could be applied in other populations, the researcher said the findings need to be replicated outside the region.

据研究团队称,该风险预测模型尚未准备好用于对无认知症状人群的常规筛查。

The risk prediction model is not yet ready for routine screening of people without cognitive symptoms, according to the research team.

该研究并未证实常规血液检测能预防痴呆或改善临床结果。(iStock)The study does not establish that routine blood testing prevents dementia or improves clinical outcomes. (iStock)

“目前尚无获批用于大脑已有病理但[无症状]人群的治疗手段,”杰克对福克斯新闻数字版表示。“因此,没有理由做这项检测。……检测结果完全不会改变你的医疗管理,因为没有可用的治疗。”他补充说,如果预防性疗法获批,这种情况可能会改变。该研究并未确立常规血液检测能预防痴呆或改善临床结局。

"There is no treatment that’s been approved for people who are [asymptomatic] but have the disease in the brain," Jack told Fox News Digital. "Therefore, there’s no reason to do the test. … The results of the test would not change your medical management at all since there’s no treatment available." That could change if preventive treatments are approved, he added. The study does not establish that routine blood testing prevents dementia or improves clinical outcomes.

杰克补充说:“许多大脑中病理水平较低的老年人一生都不会出现症状。”他指出,一些患有阿尔茨海默病相关病理的人也可能在出现认知障碍前死于其他原因。

"Many elderly people who have the pathology in the brain at lower levels will never develop symptoms in their lifetime," Jack added, noting that some people with Alzheimer’s-related pathology may also die of another cause before developing cognitive impairment.

阅读媒体原文 ↗